Genome & Company (KOSDAQ:314130)
South Korea · Delayed Price · Currency is KRW 5,400.00
-230.00 (-4.09%)
At close: Jun 12, 2026
Genome & Company Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -5,712 | -6,428 | -20,112 | -47,466 | -51,838 | -34,117 |
Depreciation & Amortization | 6,354 | 6,672 | 7,447 | 8,272 | 9,462 | 2,591 |
Loss (Gain) From Sale of Assets | 96.9 | 76.89 | 79.51 | 77.11 | -0.69 | 12.93 |
Asset Writedown & Restructuring Costs | 3,095 | 3,095 | 8,367 | 2,325 | - | - |
Loss (Gain) From Sale of Investments | 1,017 | 583.4 | -40.28 | -46.44 | - | - |
Stock-Based Compensation | 3,566 | 3,155 | 2,342 | 12,066 | 6,083 | 5,566 |
Provision & Write-off of Bad Debts | - | - | - | - | -12.92 | - |
Other Operating Activities | -24,039 | -23,431 | -8,964 | -4,648 | -3,864 | -1,658 |
Change in Accounts Receivable | 95.27 | 153.34 | -459.04 | 1,126 | -1,145 | 11.95 |
Change in Inventory | -1,523 | -308.83 | -1,898 | -1,694 | -886.4 | -154.36 |
Change in Accounts Payable | 903.81 | 40.29 | 88.24 | 132.77 | -139.79 | 14.8 |
Change in Other Net Operating Assets | -3,124 | -1,995 | -3,182 | -2,368 | -1,209 | 1,573 |
Operating Cash Flow | -19,270 | -18,387 | -16,331 | -32,224 | -43,550 | -26,159 |
Capital Expenditures | -377.47 | -284.66 | -3,970 | -18,853 | -6,849 | -2,875 |
Sale of Property, Plant & Equipment | - | - | - | - | 0.96 | 0.5 |
Cash Acquisitions | - | - | - | - | - | -26,721 |
Sale (Purchase) of Intangibles | -140.1 | -151.18 | -216.34 | -189.09 | -427.29 | -504.78 |
Investment in Securities | -3,041 | -7,528 | 15,849 | 4,742 | 7,453 | -29,609 |
Other Investing Activities | 629.32 | 470.62 | -112.66 | -1,129 | -99.49 | -100.48 |
Investing Cash Flow | -2,929 | -7,494 | 11,551 | -15,430 | 77.52 | -59,810 |
Long-Term Debt Issued | - | 142.22 | 5,830 | 32,509 | - | - |
Long-Term Debt Repaid | - | -20,908 | -568.03 | -2,023 | -1,645 | -820.29 |
Net Debt Issued (Repaid) | 3,358 | -20,766 | 5,262 | 30,487 | -1,645 | -820.29 |
Issuance of Common Stock | - | - | 33.84 | 81.49 | 126.83 | 1,248 |
Repurchase of Common Stock | -54,155 | -54,155 | - | - | - | - |
Other Financing Activities | 27,017 | 27,023 | -49.78 | - | 35.61 | 57.69 |
Financing Cash Flow | 4,942 | -22,173 | 5,246 | 30,568 | 78,550 | 17,617 |
Foreign Exchange Rate Adjustments | -1,227 | -1,897 | 8,727 | 1,226 | 1,089 | 453.3 |
Miscellaneous Cash Flow Adjustments | -0 | -0 | 0 | -0 | 0 | -0 |
Net Cash Flow | -18,485 | -49,950 | 9,192 | -15,860 | 36,167 | -67,898 |
Free Cash Flow | -19,648 | -18,671 | -20,301 | -51,077 | -50,399 | -29,034 |
Free Cash Flow Margin | -81.81% | -75.94% | -73.17% | -357.28% | -357.83% | -6434.20% |
Free Cash Flow Per Share | -609.22 | -596.33 | -666.18 | -1808.70 | -1790.39 | -1080.03 |
Cash Interest Paid | 593.5 | 596.87 | 587.12 | 310.78 | 170.8 | 52.71 |
Cash Income Tax Paid | - | 41.21 | 70.95 | 92.92 | 54.31 | 10.84 |
Levered Free Cash Flow | -3,242 | -21,481 | -17,433 | -31,442 | -35,323 | -17,129 |
Unlevered Free Cash Flow | -553.54 | -18,531 | -15,220 | -30,355 | -35,213 | -17,095 |
Change in Working Capital | -3,648 | -2,110 | -5,451 | -2,804 | -3,379 | 1,446 |